Xiaohua Xin

TL;DR: The pharmacokinetic/pharmacodynamic relationship established for SU11248 in these preclinical studies has aided in the design, selection, and evaluation of dosing regimens being tested in human trials.

TL;DR: It is demonstrated that SU6668‐induced inhibition of angiogenic receptor tyrosine kinase activity in vivo is associated with rapid vessel killing in tumors, leading to broad and potent antitumor effects.

TL;DR: Daily oral administration of CHIR-258 at doses that inhibited FGFR3 signaling in K MS-11-luc tumors in vivo resulted in a significant inhibition of KMS-11/luc tumor growth, which translated into a significant improvement in animal survival, which provides a relevant preclinical basis for clinical trials of CHir-258 inFGFR3-positive MM patients.

TL;DR: In this paper, the authors proposed a method of treating metastatic cancer such as metastasized tumors using a compound of Structure I, a tautomer of the compound, a pharmaceutically acceptable salt of the compounds, a pharmaceutical acceptable salt or a mixture thereof.

TL;DR: An in vivo MM model in which multi-organ MM lesions developed after tail vein injection of human KMS-11-luc cells stably transfected with luciferase was developed, and CHIR-258 anti-tumor activity translated to a significant improvement of animal survival compared to vehicle treatment in this model.